1. Background {#sec1}
=============

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by degeneration of articular cartilage, synovium inflammation, imbalance in the synthesis and catabolism of the extracellular matrix of chondrocytes, and the formation of subchondral bone and osteophytes \[[@B1]\]. OA is common in the elderly, especially people older than 65 \[[@B2]\]. It is predominant in heavily loaded joints including the knee, hip, spine, and finger joints and ultimately leads to joint dysfunction \[[@B3]\]. Although there are many various therapies to relieve joint pain and improve joint function, the efficacy of these treatments is limited \[[@B4]\]. Joint replacement surgery can only treat patients at the end stage of OA, and X-ray diagnosis is not informative without visible radiographic changes in joint tissue. There is little understanding of the molecular processes involved in the pathogenesis of OA, limiting early diagnosis and effective treatment of OA. Thus, the identification of sensitive biomarkers and the development of novel drug targets at molecular level are key goals of OA research.

Together with the Human Genome Project and the rapid development of molecular biology technology, high-throughput genechip technology has emerged, allowing the rapid and simultaneous analysis of thousands of gene loci \[[@B5]\]. Use of genechips can provide insights into the molecular pathogenesis of diseases. Currently, gene expression profiles of OA have mainly focused on articular cartilage, subchondral bone, and synovium \[[@B6]--[@B8]\], but there has not been comprehensive microarray analysis of blood monocytes. Blood is more accessible than tissue, and blood sample collection is less painful for patients, so the identification of sensitive diagnostic biomarkers of OA in the peripheral blood would be highly valuable for clinical application. Peripheral blood mononuclear cells (PBMCs) participate in the occurrence and development of osteoarthritis by promoting osteoclastogenesis and bone resorption, and inhibiting osteoclast apoptosis and interleukin 1 receptor I (IL-1RI) expression \[[@B9]\]. Monocytes increase the degradation of the extracellular matrix of chondrocytes by promoting the expression of matrix metalloproteinase 13 (MMP13), an enzyme that participates in the degradation of extracellular matrix proteins \[[@B10]\]. Monocytes promote the apoptosis of chondrocytes and ultimately lead to cartilage degeneration \[[@B11]\]. Therefore, determination of gene expression profiles of osteoarthritis PBMCs will allow exploration of the molecular pathogenesis of osteoarthritis and may help identify improved targets for the treatment of osteoarthritis.

In this study, gene expression profiles of osteoarthritis PBMCs were constructed by genechip technology. Differentially expressed genes (DEGs) were screened out by comparing the genechip results of osteoarthritis patients with those of normal controls. To obtain greater insights into the molecular mechanisms of OA, we applied bioinformatics analysis. Gene ontology (GO) analysis and pathway enrichment analysis were performed for DEGs on the Gene-Cloud of Biotechnology Information (GCBI) bioinformatics platform, revealing the core genes and signaling pathways in the pathogenesis of OA. In addition, the network relationships between DEGs and signaling pathways were determined by pathway relation and gene signal network analyses, revealing key players in the molecular pathogenesis of OA.

2. Results {#sec2}
==========

2.1. Identification of Differentially Expressed Genes {#sec2.1}
-----------------------------------------------------

Gene expression profiles of peripheral blood monocytes for OA groups and control groups were compared, revealing 1231 DEGs. Of these genes, 791 were upregulated and 440 were downregulated. We ranked the differentially expressed genes according to the *P* value. The top thirty up- and downregulated DEGs are listed in [Table 1](#tab1){ref-type="table"}. The lowest *P* value of the upregulated DEGs was ribosomal protein L38 (*RPL38*; *P* = 5.30 × 10^−05^), followed by protein phosphatase 3, catalytic subunit, alpha isozyme (*PPP3CA*; *P* = 7.40 × 10^−05^). The most significant downregulated DEG was IKAROS family zinc finger 1 (*IKZF1*; *P* = 1.36*E* − 04), followed by chromosome 7 open reading frame 43 (*C7orf43*; *P* = 1.87*E* − 04). Cluster analysis was performed on the differentially expressed genes, and the result is represented as a heatmap ([Figure 1](#fig1){ref-type="fig"}).

2.2. GO Analysis and Pathway Enrichment Analysis of DEGs {#sec2.2}
--------------------------------------------------------

We next performed GO analysis of the identified DEGs and found 449 biological processes that were significantly enriched. The 30 most enriched GO terms and related DEGs are shown in [Table 2](#tab2){ref-type="table"}. We found that the DEGs were mainly enriched in small molecule metabolic process (GO:0044281, GO:0006468, and GO:0044267), immune process (GO:0045087, GO:0006955, GO:0006954, GO:0019221, and GO:0050900), cell proliferation and apoptosis (GO:0006915, GO:0008283, GO:0043065, and GO:0008219), cell cycle (GO:0000278, GO:0000090, GO:0000087, and GO:0007049), RNA splicing process (GO:0008380 and GO:0000398), and cell adhesion (GO:0030155). DEGs enriched in these biological processes included *interleukin 1*, *alpha* (*IL1A*), *interleukin 6 receptor* (*IL6R*), *interleukin 7 receptor* (*IL7R*), *protein phosphatase 3*, *catalytic subunit*, *alpha isozyme* (*PPP3CA*), *ribosomal protein L38* (*RPL38*), *phosphatidylinositol-4,5-bisphosphate 3-kinase* (*PIK3*), mitogen-activated protein kinase 14 (*MAPK14*), *tumor necrosis factor superfamily*, *member 10* (*TNFSF10*), *tumor necrosis factor superfamily*, *member 13 (TNFSF13)*, *activating transcription factor 2* (*ATF2*), and others. The DEGs mapped to 143 pathways, and the pathway enrichment analysis is partly presented in [Table 3](#tab3){ref-type="table"}. Many of the genes with altered expression participate in osteoclast differentiation, apoptosis, focal adhesion, and cell cycle. In addition, many DEGs are parts of signaling pathways like the MAPK, PI3K-Akt, calcium, T-cell receptor, and wnt and Jak-STAT signaling pathways. *Tyrosine kinase 2* (*TYK2*), *phosphatidylinositol-4*,*5-bisphosphate 3-kinase*, *catalytic subunit alpha* (*PIK3CA*), *phosphatidylinositol-4,5-bisphosphate 3-kinase*, *catalytic subunit beta* (*PIK3CB)*, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (*PIK3CD*), *phosphoinositide-3-kinase*, *regulatory subunit 1* (*PIK3R1*), *MAPK14*, *IL1A*, *jun D proto-oncogene* (*JUND*), *FOS-like antigen 2* (*FOSL2*), and *PPP3CA* genes are related to osteoclast differentiation, and *IL-1A*, *JUND*, *PPP3CA*, and *MAPK14* are involved in the MAPK signaling pathway.

2.3. Network Analysis {#sec2.3}
---------------------

The geneSignalNetwork analysis was performed on 1231 DEGs and revealed interactions between 183 DEGs ([Figure 2](#fig2){ref-type="fig"}). The results showed that *phospholipase C*, *beta 1 (PLCB1)*, *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3R1*, *v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog* (*KRAS*), *MAPK14*, *protein kinase*, *cAMP-dependent*, *catalytic*, *beta* (*PRKACB*), *phosphatidylinositol-4-phosphate 5-kinase*, *type I*, *alpha* (*PIP5K1A*), *G protein*, *alpha inhibiting activity polypeptide 2* (*GNAI2*), *G protein*, *alpha inhibiting activity polypeptide 3* (*GNAI3*), *calmodulin 1* (*CALM1*), *G protein*, *beta polypeptide 2* (*GNB2*), *G protein*, *gamma 11* (*GNG11*), *beta-actin* (*ACTB*), and *Rac family small GTPase2* (*RAC2*) interact with more than 10 DEGs, making them core genes in the network. The network relationship of DEGs related to osteoclast differentiation, including *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3R1*, *MAPK14*, *JUND*, *FOSL2*, *IL1A,* and *PPP3CA*, is shown in [Figure 3](#fig3){ref-type="fig"}.

The pathwayRelationNetwork analysis was also performed and revealed interaction relationships between 68 pathways ([Figure 4](#fig4){ref-type="fig"}). The MAPK signaling pathway, apoptosis, pathways in cancer, cell cycle, p53 signaling pathway, calcium signaling pathway, wnt signaling pathway, adherens junction, ErbB signaling pathway, focal adhesion, regulation of actin cytoskeleton, ubiquitin-mediated proteolysis, TGF-beta signaling pathway, and pancreatic cancer interacted with more than 10 pathways, making these core pathways. The most significant pathway in this analysis was the MAPK signaling pathway and its related pathways, as shown in [Figure 5](#fig5){ref-type="fig"}. The calcium signaling pathway, cell cycle, wnt signaling pathway, TGF-beta signaling pathway, and VEGF signaling pathway were the source pathways of MAPK signaling pathway. Moreover, MAPK signaling pathway regulated apoptosis, cell cycle, wnt signaling pathway, p53 signaling pathway, and phosphatidylinositol signaling system.

3. Discussion {#sec3}
=============

In the present study, the Human Genome U133A genechip from Affymetrix was used to detect the gene expression profiles of PBMCs from 19 patients with osteoarthritis and 22 healthy controls. We identified 1231 DEGs, with 791 upregulated DEGs and 440 downregulated DEGs. The top 10 most significant DEGs according to the *p* value were *RPL38*, *PPP3CA*, *TROVE domain family*, *member 2* (*TROVE2*), *PRP40 pre-mRNA processing factor 40 homolog A* (*PRPF40A*), *centrosomal protein 350 kDa* (*CEP350*), *IKAROS family zinc finger 1* (*IKZF1*), *mitochondrial ribosomal protein S31 (MRPS31)*, *RAB11A*, *member RAS oncogene family* (*RAB11A*), zinc finger CCCH-type containing 14 (*ZC3H14*), and *chromosome 7 open reading frame 43* (*C7orf43*). The most significant upregulated DEG was *RPL38*, which affects processes of gene expression, DNA transcription, gene translation, and cell proliferation. Normal expression of ribosomal protein L29 (RPL29) is essential for chondrocyte proliferation and skeletal growth, and high expression level of RPL29 inhibited chondrocyte terminal differentiation, keeping cells in a state of abnormal proliferation \[[@B12]\]. Altered expression of RPL29 also influenced the rate of extracellular matrix protein synthesis \[[@B13]\]. Green et al. found different expressions of ribosomal protein L10 (RPL10) during endochondral bone development, suggesting effects on cell differentiation before bone mineralization \[[@B14]\]. Given effects of other ribosomal proteins, we hypothesize that ribosomal protein RPL38 may participate in the pathogenesis of OA by inhibiting chondrocyte differentiation and proliferation, decreasing the synthesis of the extracellular matrix.

Osteoclasts are closely related to bone resorption and subchondral bone remodeling processes involved in the pathophysiology of OA \[[@B15]\]. Osteoclasts are large multinucleated cells which originate from hematopoietic precursors of the monocyte-macrophage lineage \[[@B16]\]. Durand et al. found PBMCs from OA patients display increased osteoclastogenesis and bone resorption \[[@B9]\]. Our pathway enrichment analysis of DEGs support previous findings and suggest that the osteoclast differentiation pathway contributes to OA development. *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3R1*, *MAPK14*, *IL1A*, *JUND*, *FOSL2*, and *PPP3CA* were the gene symbols of osteoclast differentiation pathway, and these genes showed increased expression in PBMCs of OA patients compared to normal controls. This suggests that mononuclear cells from patients with OA have stronger osteoclast differentiation ability. PIK3CA, PIK3CB, PIK3CD, and PIK3R1 belong to the PI3Ks (phosphoinositide-3-kinases) family \[[@B17]\]. PI3K is not only involved in osteoclast differentiation, activation, and survival but also contributes to osteoclast-mediated bone resorption and in vivo bone homeostasis \[[@B18]\]. PI3K inhibitors such as wortmannin and LY294002 inhibit osteoclast chemotaxis, attachment, and spreading \[[@B19]\]. The PI3K isoform PIK3CB also promotes osteoclast development and bone resorption \[[@B20]\]. JUND and FOSL2 belong to the activator protein-1 (AP-1) transcriptional factor family, which regulates many cellular processes such as differentiation, proliferation, and apoptosis \[[@B21]\]. Fos is a necessary factor for the differentiation of hematopoietic precursor cells into osteoclasts. Mice deficient in Fos (Fos-/-) develop osteopetrosis and show high bone mineral density and defective osteoclast formation. Fos1 transgenic mice showed increased production of osteoclasts and active bone resorption \[[@B22]\]. The JUND/FOSL2 heterodimer upregulates the expression of *Tcirg1* to increase osteoclastogenesis \[[@B23]\]. IL-1A, as a proinflammatory cytokine, can disrupt bone metastasis and stimulate osteoclast resorption activity \[[@B24]\]. PPP3CA, or calcineurin 1, is a serine/threonine-specific phosphatase regulated by Ca^2+^/calmodulin \[[@B25]\]. PPP3C has effects in tumors, cardiovascular system, immune system, and nervous system \[[@B26]\]. The dephosphorylation of PPP3C helps regulate cell proliferation and differentiation in the cytokine-mediated activation of immune cells \[[@B27]\]. Collectively, all these upregulated DEGs associated with osteoclast differentiation may promote the development of OA and have potential to serve as novel biomarkers to monitor changes of OA and are potential drug targets for the treatment of OA.

The most significant pathway revealed by network analysis was the MAPK signaling pathway, with an occupied core position in the network. The MAPK signaling pathway as the source pathway can regulate apoptosis, cell cycle, wnt signaling pathway, p53 signaling pathway, and the phosphatidylinositol signaling system. MAPKs are serine/threonine protein kinases, and activating a protein kinase cascade (MAPKKK-MAPKK-MAPK) allows the transduction of extracellular signals into the nucleus. In this way, the expression of genes related to cell proliferation, differentiation, apoptosis, and stress response can be regulated \[[@B28]\]. The MAPK signaling pathway plays a variety of roles in OA. First, p38-MAPK promotes chondrocyte apoptosis through Fas-mediated apoptotic pathway and activation of ATF-2, caspase-3, and p53 \[[@B29]\]. Second, p38-MAPK induces the expression of MMP13, promotes the degradation of collagen II in the extracellular matrix of chondrocytes, and inhibits the synthesis and secretion of collagen and glycoprotein \[[@B30]\]. Third, p38-MAPK upregulates expression of cyclooxygenase-2 (COX2), prostaglandin E2 (PGE2), and inducible nitric oxide synthase (iNOS), and increases the synthesis of inflammatory mediators, leading to joint swelling, pain, and cartilage destruction \[[@B31]\]. Fourth, p38-MAPK is essential for the differentiation of osteoclast precursor cells into osteoclasts as well as osteoclast maturation and survival \[[@B32]\]. In our analysis of DEGs enriched in the osteoclast differentiation pathway, we found that PIK3CA, PIK3CB, PIK3CD, and PIK3R1 indirectly activate MAPK14, the prototypic member of the p38-MAPK family, through phosphorylation. MAPK14 is a key upstream gene that activates the expression of downstream genes such as IL1A, JUND, FOSL2, and PPP3CA. The network relationships between these genes revealed that PI3Ks may regulate IL1A, JUND, FOSL2, and PPP3CA through the MAPK signaling pathway. However, these regulatory relationships require further experiment to verify.

The results of this study have similarities and differences with published microarray analysis on synovial fluid, synovium membranes, subchondral bone, and cartilage. Firstly, the biological processes enriched by some DEGs are the same, such as immune response and inflammatory response (IL, TNF, TLR, and TGF-*β*), cell cycle (TGF-*β* and SMAD2), cell apoptosis (CASP and BAX). Secondly, high expression of proteinase (ADAMTS10) is same. Thirdly, some signal pathways enriched by DEGs are the same (MAPK signaling pathway, TOLL-like signaling pathway, and TGF-*β* signaling pathway) \[[@B6]--[@B8]\]. However, this study found that the main signal pathway enriched by DEGs was osteoclast differentiation, which may be related to the fact that peripheral blood mononuclear cells are precursors of osteoclasts. Only a small portion of the DEGs have the same results as previous tissue microarray because gene expression of PBMCs is affected by several processes. Attur et al. \[[@B33]\] showed that PBMCs can be activated by the inflammatory process of osteoarthritis when they pass through different tissues of the joint. DEGs in PBMCs may reflect the susceptibility of OA from a genetic perspective.

4. Conclusions {#sec4}
==============

Gene expression profiles were determined for PBMCs in OA patients and healthy controls. Analysis revealed 1231 DEGs, with 791 upregulated DEGs and 440 downregulated DEGs. The most significant upregulated DEG was RPL38, which may inhibit chondrocyte differentiation and synthesis of the extracellular matrix. *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3R1*, *MAPK14*, *IL1A*, *JUND*, *FOSL2*, and *PPP3CA* were the gene symbols of the osteoclast differentiation pathway. These genes promote the development of OA through increasing osteoclastogenesis. PI3Ks may also regulate IL1A, JUND, FOSL2, and PPP3CA through the MAPK signaling pathway. The discovery of these molecular mechanisms associated with the progression of osteoarthritis may contribute to the early diagnosis and treatment of osteoarthritis. Further work should evaluate the utility of these DEGs as biomarkers with diagnostic efficiency, as well as their potential as novel drug targets for the treatment of OA.

5. Methods {#sec5}
==========

5.1. Research Subjects {#sec5.1}
----------------------

The research subjects consisted of 19 OA patients and 22 healthy controls. All the research subjects were collected from Department of Rheumatology and Immunology, the second Xiangya Hospital of Central South University. The symptomatic primary OA patients who met the inclusion criteria were diagnosed by American College of Rheumatology(ACR) standard diagnostic criteria \[[@B34]\], with the Kellgren and Lawrence scoring system rating over grade 1 \[[@B35]\]. The Kellgren and Lawrence scoring system is divided into five grades: grade 0 means normal radiograph; grade 1 means suspicious pathology; grade 2 means small osteophytes and possible joint space narrowing; grade 3 means moderate osteophytes, definite joint space narrowing, and some of subchondral bone sclerosis; and grade 4 means large osteophytes, severe joint space narrowing, and obvious subchondral bone sclerosis. Within the 19 OA patients analyzed, there were 3 OA patients of grade 1, 4 OA patients of grade 2, 6 OA patients of grade 3, and 6 OA patients of grade 4. Exclusion criteria included the diagnosis of RA, osteoporosis, ankylosing spondylitis, neoplastic disease, or any other inflammatory autoimmune diseases. The healthy controls were collected from the same period of physical examination without clinical and radiographic osteoarthritis according to ACR criteria. The age, height, weight, and sex of OA patients and healthy controls were comparable. The research process followed the ethical standards of human experiment in Xiangya Medical College of Central South University and obtained the consent of the research subjects.

5.2. Monocyte Extraction and RNA Isolation {#sec5.2}
------------------------------------------

We collected fresh peripheral blood from each subject and separated circulating mononuclear cells (MNCs) with UNI-SEP separation tube (Novamed INC, Illinois, USA) according to manufacturer\'s recommendations. UNI-SEP products are sterile plastic centrifuge tubes containing a solution of 5.6% polysucrose and 9.6% sodium metrizoate. Then, we used monocyte negative isolation kit (Dynal Biotech ASA, Oslo, Norway) to isolate monocytes from MNCs. The antibody mix contains mouse IgG antibodies for CD2, CD7, CD16, CD19, CD56 and CD235a bound the surface of depletion dynabeads, and we discarded beads with unwanted cells and collected untouched monocytes. Then, the monocytes were lysed in TRIzol Reagent (Life Technologies, Bleiswijk, The Netherlands) for 5 min, chloroform was added, and then centrifuged (15 min at 12 000*g*). Transferring the upper aqueous phase to another RNase-free EP tube and adding isopropanol, the tube was placed stably for 10 min and then centrifuged (15 min at 12 000*g*). The sediments (RNA) were washed with 75% ethanol and dissolved in DEPC-treated water. Quality and quantity of the isolated RNA were measured by analyzing samples using the 2100 Bioanalyzer (Agilent Technologies, Amstelveen, The Netherlands) and Nanodrop spectrophotometer.

5.3. Microarray Analysis {#sec5.3}
------------------------

Total RNA was reverse transcribed to synthesis first-strand cDNA by using a T7-Oligao (dT) Promoter Primer, and then second-strand cDNA was synthesized and purified. Next, in *in vitro* transcription reaction, second-strand cDNA serves as a template performed for complementary RNA (cRNA) amplification and biotin labeling and was cleaned up and fragmented. All the operations were following the instructions of MessageAmp™ Premier RNA Amplification kit (Invitrogen, USA). Subsequently, the biotinylated cRNAs were hybridized to Affymetrix Human Genome U133A genechip overnight at 45°C with rocking. Genechip was then washed and stained according to the protocol of GeneChip® Hybridization, Wash, and Stain kit (Thermo Fisher Scientific, USA). Finally, Affymetrix Gene Array Scanner G2500A scanned the chip, and the scanned images were analyzed by MAS5.0 software.

5.4. Screening of DEGs {#sec5.4}
----------------------

The image signals of the chip were transformed into the original data of gene expression level by MAS5.0 software. OA group and control group were set up on the GCBI working platform (<https://www.gcbi.com.cn/>, GMINIX Informatics Ltd. Co, Shanghai, P.R. China). The original data CEL files were imported into the two groups. Using SAM (significance analysis of microarray) R program \[[@B36]\], DEGs between OA group and control group were screened according to the screening criteria of *Q* \< 0.05, *P* \< 0.05, and fold change \> 1.2(*Q* value is the false discovery rate, which represents the expected proportion of false-positive genes in differentially expressed genes. *P* value is adjusted by the *Q* value. When *Q* \< 0.05, it can assure lower false discovery rate and higher reliability of results). Hierarchical clustering (a heatmap) was performed with these screened DEGs to identify whether they can make an obvious distinction between OA samples and control samples.

5.5. GO Analysis and Pathway Enrichment Analysis of DEGs {#sec5.5}
--------------------------------------------------------

We also performed GO (gene ontology) analysis (*P* \< 0.05, FDR, false discovery rate \< 0.05) and pathway enrichment analysis (*P* \< 0.05) for DEGs on the GCBI working platform. In GO analysis, biological processes, cell components, and molecular processes are mainly involved. In the screening of DEGs, more information is provided by biological processes. Therefore, in GO analysis on the GCBI platform, biological processes should be selected as the "analysis type" in parameter setting.

5.6. Network Analysis {#sec5.6}
---------------------

For DEGs and its associated signaling pathways, we did geneSignalNetwork and pathwayRelationNetwork analysis on the GCBI platform, so the interaction relationship of DEGs and signaling pathways was obtained.

The authors would like to acknowledge the online analysis platform GCBI for providing us technical assistance. This work was supported by the Hunan Provincial Natural Science Fund (grant no. 2016JJ4053).
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![A heatmap. The horizontal axis indicated cluster analysis of groups. Blue represented OA groups, and brown represented control groups. The vertical axis meant cluster analysis of genes. Red represented upregulated DEGs, green represented downregulated DEGs, and black represented the genes expression with no difference. The more the significant difference of gene expression, the brighter the color.](BMRI2019-4291689.001){#fig1}

![The map of DEG interaction relationship. Red nodes indicate upregulated genes, and blue nodes indicate downregulated genes. The larger the area of the node, the more important the gene in the network. The interaction relationship between genes is expressed by a connection line. The solid line without arrow indicates the interaction between DEGs is not directional, otherwise is directional. The beginning of arrow is the upstream gene, and the end of arrow is the downstream gene. The dashed line with arrow indicates the indirect interaction relationship. The solid line with flat head indicates the inhibitory interaction. The letters on the connection line are abbreviated as the type of interaction. c, compound; a, active; ind, indirect; inh, inhibition.](BMRI2019-4291689.002){#fig2}

![The network relationship of DEGs which enriched in osteoclast differentiation.](BMRI2019-4291689.003){#fig3}

![The map of signaling pathway relationship. Yellow nodes indicate the signaling pathways involved by up- and downregulated DEGs. Red nodes indicate the signaling pathways involved by upregulated DEGs. The larger the nodes, the more important they are in the network. The solid line with arrows is used to represent relationship between signaling pathways. The beginning of arrow is the upstream signaling pathway, and the end of arrows is the downstream signaling pathway.](BMRI2019-4291689.004){#fig4}

![The solar map of all associated signaling pathways of the MAPK signaling pathway.](BMRI2019-4291689.005){#fig5}

###### 

The top 30 up- and downregulated DEGs in peripheral blood mononuclear cells of patients with OA.

  Gene symbol upregulated expression   Accession number   *P* value      Fold change
  ------------------------------------ ------------------ -------------- -------------
  RPL38                                NM_000999          5.30*E* − 05   1.70
  PPP3CA                               NM_000944          7.40*E* − 05   1.42
  TROVE2                               NM_001042369       8.10*E* − 05   1.28
  PRPF40A                              NM_017892          9.50*E* − 05   1.41
  CEP350                               NM_014810          1.18*E* − 04   1.52
  TROVE2                               NM_001042369       1.47*E* − 04   1.35
  CEP350                               NM_014810          1.59*E* − 04   1.41
  MRPS31                               NM_005830          1.65*E* − 04   1.33
  RAB11A                               NM_001206836       1.84*E* − 04   1.44
  ZC3H14                               NM_001160103       1.85*E* − 04   1.35
  USP12                                NM_182488          1.96*E* − 04   1.38
  GTF2H5                               NM_207118          2.32*E* − 04   1.37
  ITPR1                                NM_001099952       2.45*E* − 04   1.35
  MTF2                                 NM_001164391       2.54*E* − 04   1.44
  CLCN3                                NM_001243372       2.59*E* − 04   1.31
  C6orf62                              NM_030939          2.94*E* − 04   1.56
  MOSPD1                               NM_019556          3.25*E* − 04   1.25
  PIGF                                 NM_002643          3.54*E* − 04   1.43
  PREPL                                NM_001042385       3.89*E* − 04   1.39
  THUMPD1                              NM_017736          4.08*E* − 04   1.37
  CEP57                                NM_001243776       4.13*E* − 04   1.41
  PHACTR2                              NM_001100164       4.41*E* − 04   1.43
  ADAMTS10                             NM_001110          4.52*E* − 04   1.28
  E2F3                                 NM_001243076       4.53*E* − 04   1.41
  ING3                                 NM_019071          4.71*E* − 04   1.49
  MYCBP2                               NM_015057          4.75*E* − 04   1.32
  USP7                                 NM_003470          4.90*E* − 04   1.39
  PHKB                                 NM_000293          5.07*E* − 04   1.28
  MED1                                 NM_004774          5.19*E* − 04   1.41
  NDUFA5                               NM_005000          5.78*E* − 04   1.51
  IKZF1                                NM_001220765       1.36*E* − 04   1.56
  C7orf43                              NM_018275          1.87*E* − 04   1.29
  RAB3D                                NM_004283          2.51*E* − 04   1.33
  CDV3                                 NM_001134422       2.59*E* − 04   1.25
  FRS3                                 NM_006653          2.64*E* − 04   1.23
  ARF3                                 NM_001659          3.46*E* − 04   1.34
  LMO4                                 NM_006769          3.64*E* − 04   1.22
  RING1                                NM_002931          4.61*E* − 04   1.23
  NADK                                 NM_001198993       5.82*E* − 04   1.36
  MTMR3                                NM_001013676       5.99*E* − 04   1.28
  PTGES2                               NM_001256335       6.04*E* − 04   1.34
  MAX                                  NM_001271068       6.32*E* − 04   1.47
  LOC100996752                         NM_019094          6.73*E* − 04   1.22
  MARS                                 NM_004990          8.23*E* − 04   1.21
  SIGLEC7                              NM_001277201       8.49*E* − 04   1.24
  DUSP3                                NM_004090          8.91*E* − 04   1.39
  TNFAIP2                              NM_006291          9.11*E* − 04   1.38
  MAT2A                                NM_005911          9.78*E* − 04   1.41
  BRD2                                 NM_001113182       1.06*E* − 03   1.44
  MED12                                NM_005120          1.23*E* − 03   1.23
  SLC25A28                             NM_031212          1.26*E* − 03   1.24
  STX16                                NM_001001433       1.44*E* − 03   1.39
  USP21                                NM_001014443       1.50*E* − 03   1.26
  TM9SF4                               NM_014742          1.55*E* − 03   1.39
  CBFB                                 NM_001755          1.57*E* − 03   1.28
  GGA2                                 NM_015044          1.60*E* − 03   1.21
  POLG                                 NM_001126131       1.61*E* − 03   1.34
  YKT6                                 NM_006555          1.68*E* − 03   1.25
  CLASRP                               NM_001278439       1.75*E* − 03   1.28
  RCN3                                 NM_020650          1.94*E* − 03   1.21

###### 

The top 30 GO terms.

  GO ID                                       GO name                                    DEG number   *P* value      FDR            Gene symbols
  ------------------------------------------- ------------------------------------------ ------------ -------------- -------------- -------------------------------------------------------------------------------------------------------------------------------
  GO:0044281                                  Small molecule metabolic process           121          1.65*E* − 34   4.62*E* − 31   PPP1CB\|PLCB1\|CALM1\|PIK3CD\|PIK3R1\|PIK3CA\|PTEN\|LYPLA1\|AMD1\|SACM1L\|ARF3\| INSIG1\|PDK3\|ABHD5\|CHKB\|IMPA1,...
  GO:0007165                                  Signal transduction                        100          1.19*E* − 31   1.66*E* − 28   IL7R\|TNFSF12\|TNFSF10\|TNFSF4\|PPP2R5C\|PLCB1\|CALM1\|PIK3CB\|PIK3CD\|CASP1\| TLR1\| RAC2\|STAT6\|MAPK14\|CAMK1\|PAK2,...
  GO:0045087                                  Innate immune response                     64           1.57*E* − 24   1.47*E* − 21   CASP1\|ATF1\|PIK3CA\|PIK3R1\|MAP3K7\|MAP3K5\|KRAS\|TLR1\|PTEN\|
  ATF2\|CFP\|PTPN11\| IRF7\|ACTB\|CALM1,...                                                                                          
  GO:0010467                                  Gene expression                            69           1.53*E* − 23   1.07*E* − 20   TNFSF13\|PPP2R1A\|RPL38\|MAPK14\|KARS\|SMAD2\|AIMP1\|DICER1,...
  GO:0006915                                  Apoptotic process                          66           5.32*E* − 22   2.98*E* − 19   IL1A\|TNFSF10\|TNFSF12\|MAP3K7\|CASP1\|BAX\|RAD21\|DICER1\|CASP4\|PTEN\|H1F0\|FXR1\|PSMD12\|DAB2\|CST3,...
  GO:0000278                                  Mitotic cell cycle                         47           2.64*E* − 20   1.23*E* − 17   PPP1R12A\|PPP1CB\|PPP2R1A\|NSL1\|RFC5\|RAD21\|RBL2\|RPA1\|CEP63...
  GO:0006351                                  Transcription, DNA-dependent               114          1.32*E* − 19   5.28*E* − 17   MAP3K7\|ATF1\|ATF6\|STAT6\|FOSL2\|ASF1A\|BBX\|UCHL5\|ATXN1\|INO80 B\|KANK2\|CEBPE\|SIRT1\| SETD2\|IRF5\| BRD2\|IKZF1\|RB1,...
  GO:0019221                                  Cytokine-mediated signaling pathway        27           1.63*E* − 19   5.70*E* − 17   IL1A\|IL6R\|STAT2\|STAT6\|KRAS\|CEBPA\|PTPN11\|CD44\|IRF7\|IRF5\|IRF3\|IRAK3\|ZC3H15\|CCR1,...
  GO:0019048                                  Virus-host interaction                     42           4.74*E* − 19   1.48*E* − 16   MAP3K5\|PIK3R1\|KARS\|BAX\|TGFB1\|CCR3\|MDFIC\| RB1\|SIRT1,...
  GO:0006468                                  Protein phosphorylation                    43           2.25*E* − 18   6.30*E* − 16   MAP3K11\|MAP4K4\|PIK3R1\|PIK3CA\|TGFB1\|ADAM10\|IRAK3\|HIPK3\|SMAD2\| TLK1\|CREB1\|FYB\|STK11,...
  GO:0008380                                  RNA splicing                               34           3.49*E* − 16   7.52*E* − 14   PPP2R1A\|SRSF11\|PABPN1\|CPSF1\|SRSF3\|CLASRP,...
  GO:0015031                                  Protein transport                          43           3.87*E* − 16   7.73*E* − 14   RAB3D\|ARRB2\|RAB11A\|ACAP1\|NMD3\|ARF3,...
  GO:0044267                                  Cellular protein metabolic process         45           4.71*E* − 13   6.94*E* − 11   ATF1\|RPL38\|ACTB\|ATF6\|CPA3\|EIF4B\|ETF1\|SPCS2\|CXXC1\|ALG5\|CCT6A,...
  GO:0000090                                  Mitotic anaphase                           24           4.61*E* − 12   5.87*E* − 10   PPP2R1A\|RAD21\|PDS5A\|PSMD3\|SMC3\|CLASP2,...
  GO:0000087                                  M phase of mitotic cell cycle              26           7.27*E* − 12   8.85*E* − 10   PPP2R1A\|PSMD4\|CLASP2\|PSME3\|ANAPC5\|RAD21\|RANBP2,...
  GO:0000398                                  mRNA splicing via spliceosome              24           7.84*E* − 12   9.15*E* − 10   SRSF11\|PABPN1\|CLP1\|RBM22\|PAPOLA\|FUS\|POLR2E\|TRA2A\|PRPF4B,...
  GO:0001525                                  Angiogenesis                               24           9.13*E* − 12   1.02*E* − 09   TNFSF12\|MAP3K7\|MAPK14\|PIK3CA\|ELK3\|DICER1\|SIRT1,...
  GO:0002224                                  Toll-like receptor signaling pathway       19           3.87*E* − 11   3.87*E* − 09   MAP3K7\|MAPK14\|TLR7\|IRF7\|ATF1\|ATF2\|DUSP3\|IRF3\|HSP90B1\|RPS6KA5\|BTK\| UNC93B1\|ELK1\|BCL10\|UBE2D1,...
  GO:0007049                                  Cell cycle                                 24           4.71*E* − 11   4.55*E* − 09   PPP1CA\|CAMK1\|RB1CC1\|CREBL2\|PARD6A\|CYLD\|TLK1\| IKZF1,...
  GO:0006955                                  Immune response                            29           7.21*E* − 11   6.73*E* − 09   IL1A\|IL7R\|IL1RN\|TNFSF10\|TNFSF4\|TNFSF13\|TLR1\|CCR1\|IKBKAP,...
  GO:0008283                                  Cell proliferation                         29           5.42*E* − 10   4.27*E* − 08   IL1A\|RBL38\|MAP3K11\|PTEN\|DAB2\|FES\|PA2G4\|ASCC3\|MS4A2,...
  GO:0030155                                  Regulation of cell adhesion                10           5.49*E* − 10   4.27*E* − 08   PPP2R1A\|PPP1R12 A\|PPP1CB\|CYTH4\|PTK2B\| CYTIP\| ENG\|GSN,...
  GO:0050852                                  T-cell receptor signaling pathway          16           6.55*E* − 10   4.96*E* − 08   MAP3K7\|PIK3CA\|PIK3CB\|PIK3R1\|PIK3CD\|RBCK1\|PAK2\|FYB\|UBE2N\|PTEN\|WAS\|FYN\|NCK1\|MALT1\|CD4\| BCL1
  GO:0043065                                  Positive regulation of apoptotic process   20           8.03*E* − 10   5.92*E* − 08   TNFSF10\|PPP2R4\|MAP3K5\|PIK3R1\|TGFB1\|ATM\|SIRT1\|DNM2\|LILRB1\|CTNNB1\|TSPO\|HMGB1\|BAX\|ING3\|IRF5\|PRKDC,...
  GO:0051403                                  Stress-activated MAPK cascade              10           1.92*E* − 09   1.38*E* − 07   MAPK14\|MAP3K7\|ATF1\|ATF2\|ELK1\|DUSP3\|RPS6KA3\|CREB1\|RPS6KA1\|RPS6KA5
  GO:0007010                                  Cytoskeleton organization                  10           4.27*E* − 09   2.49*E* − 07   PRPF40 A\|PHIP\|SIPA1\|PLD2\|SVIL\|PXN\|TPM1\|ZMYM4\|CAPZB,...
  GO:0050900                                  Leukocyte migration                        14           6.19*E* − 09   3.54*E* − 07   PIK3CB\| PIK3CA\|PIK3R1\|KRAS\|SIRPA\| PTPN11\|FYN\|ITGB7,...
  GO:0006954                                  Inflammatory response                      19           1.11*E* − 08   6.21*E* − 07   IL1A\|PIK3CD\|TLR1\|TLR7\|STAB1\|TGFB1\|HRH4\|CCR3\|CCR1\|LTB4R,...
  GO:0008219                                  Cell death                                 16           8.44*E* − 08   3.94*E* − 06   MAP3K11\|BCL10\|FOSL2\|CLN3\|ATXN7\|DCTN1\|FUS\|,...
  GO:0006281                                  DNA repair                                 30           9.06*E* − 08   4.16*E* − 06   BTG2\|RFC5\|SMC3\|RPA1\|TDG\|CSNK1D\|REV1,...

###### 

Results of pathway enrichment analysis of DEGs.

  Pathway name                           DEG number   *P* value      Gene symbols
  -------------------------------------- ------------ -------------- ---------------------------------------------------------------------------------------------------
  Osteoclast differentiation             26           6.26*E* − 16   TYK2\|PIK3CA\|PIK3CB\|PIK3CD\|PIK3R1\|IL1A\|PPP3CA\|JUND\|FOSL2\|MAPK14\|MAP3K7\|STAT2\|TGFB1,...
  Metabolic pathways                     79           2.81*E* − 15   COX11\|PIP5K1A\|PLCB1\|CHPF2\|ALOX5\|TPK1,...
  PI3K-Akt signaling pathway             34           1.77*E* − 11   IL7R\|IL6R\|PPP2R5C\|PPP2R1A\|PIK3CB\|PIK3CD\|PIK3CA\|ATF2,...
  MAPK signaling pathway                 28           1.34*E* − 10   IL1A\|PPP3CA\|JUND\|MAPK14\|MAP3K5\|MAP3K7\|KRAS\|TGFB1,...
  Chemokine signaling pathway            24           1.39*E* − 10   PLCB1\|CCR1\|CCR3\|PIK3R1\|PIK3CD\|PIK3CB\|PIK3CA\|KRAS\|RAC2\|STAT2,...
  T-cell receptor signaling pathway      17           2.29*E* − 09   PPP3CA\|MAPK14\|MAP3K7\|PIK3CD\|PIK3CB\|PIK3R1\|PIK3CA\|KRAS\|BCL10,...
  Focal adhesion                         23           3.28*E* − 09   PPP1CA\|PPP1CB\|ACTB\|PIK3CA\|PIK3CD\|PIK3CB\|PTEN,...
  Apoptosis                              15           6.96*E* − 09   IL1A\|TNFSF10\|TNFRSF10B\|PIK3CD\|PIK3CB\|PIK3CA\|BAX\|IRAK3,...
  Pathways in cancer                     27           9.27*E* − 08   PIK3CA\|PIK3CB\|PIK3R1\|PIK3CD\|KRAS\|PTEN\|MAX\|RAC2,...
  Cell cycle                             16           1.29*E* − 07   ANAPC5\|TGFB1\|SMAD2\|ATM\|RBL2\|RB1,...
  VEGF signaling pathway                 11           1.26*E* − 06   PPP3CA\|MAPK14\|PIK3CA\|PIK3CD\|PIK3R1\|PIK3CB\|RAC2\|KRAS,...
  Toll-like receptor signaling pathway   11           1.37*E* − 04   MAPK14\|MAP3K7\|PIK3CD\|PIK3R1\|PIK3CA\|PIK3CB\|TLR7\|TLR1\|IRF5\|IRF7,...
  Calcium signaling pathway              14           3.47*E* − 04   PPP3CA\|PLCB1\|CALM1\|ITPR1\|ITPR2\|PTK2B,...
  p53 signaling pathway                  8            4.91*E* − 04   TNFRSF10B\|ATM\|PTEN\|THBS1\|BAX\|CCNG2\|CCNG1,...
  Wnt signaling pathway                  10           5.49*E* − 03   PPP3CA\|MAP3K7\|PLCB1\|RAC2\|CHP\|,...
  TGF-*β* signaling pathway              7            7.29*E* − 03   PPP2R1A\|TGFB1\|SMAD2\|SMURF2,...
  Jak-STAT signaling pathway             10           1.11*E* − 02   IL7R\|IL6R\|PIK3R1\|PIK3CA\|PIK3CD\|PIK3CB\|STAT2\|STAT6,...
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